#Augtyro
LightNews LightNews
oncodaily.bsky.social
Repotrectinib (Augtyro) 2025 Updates: Uses in Cancer, Side effects, Dosage, Expectations, and more

oncodaily.com/drugs/repotr...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Repotrectinib #Augtyro #LungCancer #TargetTherapy
Repotrectinib (Augtyro) 2025 Updates: Uses in Cancer, Side effects, Dosage, Expectations and more - OncoDaily
Learn about Repotrectinib (Augtyo), its used, mechanism of action, side effects, dosage, and what to expect during treatment.
oncodaily.com
August 15, 2025 at 12:22 AM
cancergrace.bsky.social
In November 2023, the (FDA) approved repotrectinib (Augtyro) for the treatment of some advanced lung cancers that have a genetic change called a ROS1 gene fusion.

The complete results of the clinical trial that led to the approval have been published.
www.cancer.gov/news-events/...
March 8, 2024 at 11:55 PM
scitube.bsky.social
Understanding the structure of cancer drugs can help support better drug development. Dr James Kaduk’s work maps the structure of repotrectinib, helping researchers learn more about how this important cancer treatment is built. Watch here: scitube.io/dr-james-kad...
doi.org/10.1017/S0885715625100882
Dr James Kaduk | Mapping a Cancer Drug’s Structure Towards Better Drug Development - SciTube
Repotrectinib, sold under the brand name Augtyro, is a targeted therapy approved for the treatment of advanced non-small cell lung cancer. Specifically, it blocks a mutated protein called ROS1, which ...
scitube.io
June 17, 2026 at 1:28 PM
247qualitymeds.bsky.social
Buy Repotrectinib in India: 247qualitymeds.com/product/repo...
Buy Repotrectinib (Augtyro) Capsules in India | 24/7 QualityMeds
Buy Repotrectinib (Augtyro) Capsules Online in India. Enquire today for prescription-based access, import support, and medicine procurement.
247qualitymeds.com
August 11, 2026 at 5:28 AM
notreload.bsky.social
Other approved ROS1 inhibitors include $BMY's AUGTYRO, $PFE's XALKORI and Roche's ROZLYTREK.

Jones Research believes that the warnings and precautions on the Ibtrozi label are "as expected," in line with those of other drugs in its class, and better than those of similar drugs.
June 11, 2025 at 7:46 PM
oncodaily.bsky.social
Bristol Myers Squibb - Augtyro Listed on PBS for ROS1-Positive NSCLC

@bms-news.bsky.social

oncodaily.com/voices/brist...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Repotrectinib #RareCancer #NSCLC
Bristol Myers Squibb: Augtyro Listed on PBS for ROS1-Positive NSCLC - OncoDaily
Bristol Myers Squibb: Augtyro Listed on PBS for ROS1-Positive NSCLC / A John Iafrate, Adriana Gonzalez, Alice T Shaw, Augtyro, Bristol Myers Squibb, cancer,
oncodaily.com
April 5, 2026 at 6:02 PM
dengyuemedicine.bsky.social
La NMPA de China aprueba condicionalmente las cápsulas de Repotrectinib

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Repotrectinib #AUGTYRO #CáncerDePulmón #NSCLC #ROS1positivo #TRK #InhibidorTRK #BristolMyersSquibb #AprobaciónCondicional #NMPA
December 4, 2025 at 6:56 AM
biobonanos.bsky.social
BMS's Augtyro repotrectinib, obtained via its $4.1b takeout of Turning Point, is under FDA review again. Already approved for ROS1-positive NSCLC, it has a June 15 PDUFA date (priority review) to treat NTRK-positive solid tumors: www.prnewswire.com/news-release...
February 14, 2024 at 1:02 PM
stocktitan.net
#ZLAB Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

https://www.stocktitan.net/news/ZLAB/zai-lab-announces-national-medical-products-administration-nmpa-ht99a5hrp85q.html
China clears new AUGTYRO use for adults with NTRK‑positive cancers
China’s NMPA okays an sNDA for AUGTYRO in NTRK fusion‑positive solid tumors, its second indication after ROS1‑positive NSCLC, backed by TRIDENT‑1 data.
www.stocktitan.net
January 6, 2026 at 12:30 PM
stocktitan.net
#ZLAB Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

#stocks #investing #StockMarket

https://www.stocktitan.net/news/ZLAB/zai-lab-announces-the-inclusion-of-augtyro-repotrectinib-for-ros1-op5875ps735m.html
Zai Lab's AUGTYRO Added to China's NRDL, Expanding Cancer Treatment Access | ZLAB Stock News
Zai Lab secures major win as AUGTYRO joins China's National Reimbursement Drug List for lung cancer treatment, alongside renewals for NUZYRA and QINLOCK, enhancing affordability.
www.stocktitan.net
November 28, 2024 at 4:05 AM
geniousgrow.bsky.social
Zai Lab Announces the Inclusion of AUGTYRO ® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL)…
Zai Lab Announces the Inclusion of AUGTYRO ® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: AUGTYRO ® (repotrectinib) is included in the NRDL for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC);
geniousgrow.online
November 28, 2024 at 4:28 AM
l2plabs.bsky.social
Drug Trials Snapshots: AUGTYRO
AUGTYRO is a drug used to treat adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
dlvr.it
April 29, 2026 at 3:04 PM
oncoassist.bsky.social
🚨Latest National Medical Products Administration (NMPA) Approval!

✅ Zai Lab’s AUGTYRO™ (repotrectinib) approved in China for adult patients with neurotrophic tyrosine receptor kinase (NTRK) fusion positive solid tumors.
January 7, 2026 at 12:13 PM